JPS58118515A - ２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤 - Google Patents
２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤Info
- Publication number
- JPS58118515A JPS58118515A JP21310881A JP21310881A JPS58118515A JP S58118515 A JPS58118515 A JP S58118515A JP 21310881 A JP21310881 A JP 21310881A JP 21310881 A JP21310881 A JP 21310881A JP S58118515 A JPS58118515 A JP S58118515A
- Authority
- JP
- Japan
- Prior art keywords
- lactone
- hydroxyvitamin
- calcium
- adjusting agent
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 36
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 title claims abstract 4
- IJNDMZIDDKVXHR-MYEQSZOMSA-N 25-Hydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C/1C(CC[C@@H](O)C\1)=C)C)[C@@H]1C[C@@](C)(O)C(=O)O1 IJNDMZIDDKVXHR-MYEQSZOMSA-N 0.000 title abstract 3
- 210000002966 serum Anatomy 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims description 5
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 208000037147 Hypercalcaemia Diseases 0.000 abstract description 4
- 206010020590 Hypercalciuria Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 230000000148 hypercalcaemia Effects 0.000 abstract description 4
- 208000030915 hypercalcemia disease Diseases 0.000 abstract description 4
- 230000001766 physiological effect Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 208000001132 Osteoporosis Diseases 0.000 abstract description 2
- 235000020964 calcitriol Nutrition 0.000 abstract description 2
- 239000011612 calcitriol Substances 0.000 abstract description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 abstract description 2
- 208000005368 osteomalacia Diseases 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000005445 natural material Substances 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 3
- 235000021318 Calcifediol Nutrition 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000208235 Borassus flabellifer Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21310881A JPS58118515A (ja) | 1981-12-29 | 1981-12-29 | ２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤 |
| DE19823247836 DE3247836A1 (de) | 1981-12-29 | 1982-12-23 | Arzneimittel und verwendung derselben zur steuerung der serumcalciumkonzentration bei warmbluetern |
| FR8222038A FR2518881B1 (fr) | 1981-12-29 | 1982-12-29 | Medicaments a base de 26,23-lactones de la 25-hydroxyvitamine d3, utiles notamment pour agir sur la concentration en calcium du serum |
| US06/454,309 US4511564A (en) | 1981-12-29 | 1982-12-29 | Methods of controlling the concentration of calcium in the serum of warm-blooded animals and pharmaceutical compositions to be used therefor |
| CH7617/82A CH652929A5 (de) | 1981-12-29 | 1982-12-29 | Pharmazeutisches praeparat zur regulierung der konzentration an calcium im serum von menschen und warmbluetigen tieren und peroxylactone. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21310881A JPS58118515A (ja) | 1981-12-29 | 1981-12-29 | ２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58118515A true JPS58118515A (ja) | 1983-07-14 |
| JPS6342606B2 JPS6342606B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-08-24 |
Family
ID=16633707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21310881A Granted JPS58118515A (ja) | 1981-12-29 | 1981-12-29 | ２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58118515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62149619A (ja) * | 1985-09-05 | 1987-07-03 | Teijin Ltd | 活性型ビタミンｄ３類注射用組成物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56500045A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1979-01-26 | 1981-01-16 |
-
1981
- 1981-12-29 JP JP21310881A patent/JPS58118515A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56500045A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1979-01-26 | 1981-01-16 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62149619A (ja) * | 1985-09-05 | 1987-07-03 | Teijin Ltd | 活性型ビタミンｄ３類注射用組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6342606B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2125476C (en) | 20-methyl-substituted vitamin d derivatives | |
| Baxter et al. | Stimulation of 25-hydroxyvitamin D3-1alpha-hydroxylase by phosphate depletion. | |
| JP4493340B2 (ja) | １α−ヒドロキシ−２−メチレン−１９−ノル−プレグナカルシフェロール及びその使用 | |
| JP5113766B2 (ja) | ビタミンｄ類似体：ｒａｋ、その方法および使用 | |
| US4335120A (en) | Administration of biologically active vitamin D3 and vitamin D2 materials | |
| JP2009525980A (ja) | ビタミンｄ類似体：ｎｅｌ、その方法および使用 | |
| JP2004512276A (ja) | １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用 | |
| HU211963A9 (en) | Novel 1alpha-hydroxy vitamin d4 and novel intermediates and analogues | |
| EP1082298A2 (en) | 1$g(a)-HYDROXY-25-ENE-VITAMIN D, ANALOGS AND USES THEREOF | |
| JPH02288854A (ja) | １α，２５―ジヒドロキシル化ビタミンＤ↓２ | |
| CA2446149C (fr) | Analogues de la vitamine d | |
| IE49753B1 (en) | 24,24-difluoro-cyclovitamin d3 derivatives | |
| Omdahl et al. | Mediation of calcium adaptation by 1, 25-dihydroxycholecalciferol | |
| JPS58118515A (ja) | ２５‐ヒドロキシビタミンｄ↓３―２６，２３‐ラクトンを含有する血清カルシュウム低下剤 | |
| WO1989010352A1 (en) | SIDE CHAIN UNSATURATED 1alpha-HYDROXYVITAMIN D HOMOLOGS | |
| KR20010020343A (ko) | 비스 씨-20 측쇄를 갖는 비타민 디3 유사체 | |
| JP2009533483A (ja) | ２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用 | |
| JPS60501261A (ja) | １α，２５―ジヒドロキシル化ビタミンＤ↓２化合物及びその製造方法 | |
| JPS6341370B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO1998024762A1 (en) | Vitamin d3 derivatives | |
| JP2013512259A (ja) | ２−メチレン−１９，２６−ノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３ | |
| Uskoković et al. | The 16-ene analogs of 1, 25-dihydroxycholecalciferol. Synthesis and biological activity | |
| FR2518881A1 (fr) | Medicaments a base de 26,23-lactones de la 25-hydroxyvitamine d3, utiles notamment pour agir sur la concentration en calcium du serum | |
| US4223131A (en) | 25-Hydroxycholecalciferol-26,23-lactone | |
| Lawson et al. | Biological activity of 10-hydroxy-vitamin D3 implications for the steric structure of the active form of vitamin D |